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ABSTRACT
Objectives: We aimed to examine the temporal
association between selective serotonin reuptake
inhibitors (SSRI) and tricyclic antidepressant (TCA)
prescriptions and suicide-related events in children and
adolescents.
Design: Self-controlled case series.
Setting: Electronic health records were used from 479
general practices in The Health Improvement Network
(THIN) UK primary care database from 1995 to 2009.
Participants: 81 young people aged 10–18 years with
a record of completed suicide, 1496 who attempted
suicide, 1178 with suicidal ideation and 2361 with
intentional self-harm.
Main outcome measures: Incidence Rate Ratios
(IRRs) for completed and attempted suicide, suicidal
ideation and intentional self-harm.
Results: For non-fatal suicide-related behaviour, IRRs
were similar for the time the person was prescribed
either SSRIs or TCAs: IRRs increased during pre-
exposure, peaked on prescription day, were stable up
to the fourth prescription-week, and decreased after
the prescriptions were stopped. For both types of
antidepressants, IRRs were lower or similar to pre-
exposure levels during the period of prescription. For
SSRIs, there was an increase in the IRR for completed
suicide on the day of prescription (N=5; IRR=42.5,
95% CI 4.5 to 403.4), and during the fourth week of
SSRI prescription (N=2; IRR=11.3, 95% CI 1.1 to
115.6).
Conclusions: We found that a very small number of
young people were prescribed antidepressants and that
there was an absence of a sustained increase in rates
of suicide-related events in this group. There were no
systematic differences between the association of TCAs
and SSRIs and the incidence risk ratios for attempted
suicide, suicidal ideation or intentional self-harm and,
apart from the day of prescription, rates did not exceed
pre-exposure levels. The pattern of IRR for suicide for
SSRIs was similar to that found in non-fatal suicide-
related events. Our results warrant a re-evaluation of
the current prescription of SSRIs in young people. We
recommend the creation of a pragmatic registry for
active pharmacovigilance.
INTRODUCTION
Between 1% and 6% of adolescents in the
community suffer from major depressive dis-
order (MDD).1 In addition, suicide is the
third leading cause of death in 15-year-olds
to –19-year-olds at 6.9/100 000 population,
and the fourth in 10-year-olds to 14-year-olds
at 0.9/100 000 population.2 This calls for safe
and effective depression treatments in this
age group. As tricyclic antidepressants
(TCAs) lack efﬁcacy for depression treatment
in this age group and have a poor side-effect
proﬁle,3 selective serotonin reuptake inhibi-
tors (SSRIs) are the most commonly pre-
scribed pharmacological treatment for
children and adolescents.4
However, there has been concern that
SSRIs might be associated with an increased
risk of suicide-related events in paediatric
patients. Results from clinical trials led the
Expert Working Group of the Committee on
Safety of Medicines (CSM) to advise against
initiation of treatment with selective sero-
tonin inhibitors (SSRIs) for childhood
depression in the UK in December 2003.5
Fluoxetine, the only drug which is licensed
to treat depression in young people in the
UK, was exempted from this advice following
a review that concluded that there was a
ARTICLE SUMMARY
Strengths and limitations of this study
▪ Only a limited number of young people had a
prescription for an antidepressant in the year
before their suicide-related event, making it diffi-
cult to interpret the findings of this study.
▪ The self-controlled case series method inherently
controls for time-independent variables such as
genetics, location and socio-economic status.
▪ Changes in depression severity are poorly
recorded over time, which is a limitation.
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favourable balance of beneﬁts and risk.6 The US Food
and Drug Administration (FDA) issued similar advice in
2004.7
There is inconsistent evidence of an increased rate of
suicide-related events and intentional self-harm asso-
ciated with SSRIs.8 Data from randomised controlled
trials in adolescents and young adults report an
increased risk of suicide-related events.9 Part of this dif-
ference appears to depend on the methodology used. If
suicide-related events were ascertained using the
method of ‘adverse events’, there was a small but signiﬁ-
cant increase in suicidal ideation. However, if the studies
used rating scales to assess suicide-related events, most
studies showed an improvement in suicide-related
events.
The results from these trials should be interpreted
with caution, as they were not primarily designed to
measure suicide-related events and it would be unethical
to do so using placebo as a control.10 11 Moreover, none
of these trials on SSRIs recruited from a general popula-
tion setting and completed suicides have occurred in
any studies.9
Observational studies in young people have found
mixed results: some indicate that SSRIs protect from
suicide-related events12; others ﬁnd no effect13 14 or an
increase in risk of suicide-related events.15 16 These
studies, however, have methodological limitations includ-
ing small numbers, high attrition rates and, most import-
antly, confounding by severity.
We have previously shown that rates for SSRI prescrip-
tions in children and adolescents increased between
2005 and 2009.4 Neither TCAs nor SSRIs are considered
appropriate ﬁrst-line treatment by the National Institute
for Clinical Excellence (NICE) for depression in chil-
dren and adolescents. Given the risk of death in over-
dose, the lack of efﬁcacy in children and the side effects
associated with them, a prescriber would be less likely to
prescribe TCAs in preference to SSRIs for a person at
risk of suicide-related events.17
It is only when children and adolescents do not
respond to psychological treatment that treatment with
SSRIs should be considered.6 It is therefore important to
reassess the risks of existing clinical data to inform
future practice. We aimed to assess the temporal associ-
ation between the risk of completed suicide, attempted
suicide, suicidal thoughts, intentional self-harm and anti-
depressant prescription in adolescents, comparing SSRIs
and TCAs and correcting for age and gender, using a
large UK primary care database.
METHODS
Data source
We used data from The Health Improvement Network
(THIN) primary care database, including information
from UK primary care data prospectively recorded
between 1 January 1995 and 31 December 2009. THIN
includes anonymised general practice records on more
than 9 million patients from 479 practices in the UK
and is one of the largest primary care databases available
internationally. It is broadly representative of the UK
general practice population in terms of demographics
and consultation behaviour.18 Data on diagnoses, inter-
ventions, symptoms and referrals to secondary care are
electronically recorded as Read codes, a hierarchical
coding system used in UK primary care.19 All prescrip-
tions are also electronically recorded. Clinical diagnoses
recorded using Read codes have recently been shown to
be accurate compared with other reliable sources.20
Study population
This study included a cohort of young people and ado-
lescents, aged 10–18 years, who had a record of a
suicide-related event. Patients were included if they were
registered with a practice for at least 6 months between
January 1995 and December 2009. Patients were fol-
lowed up from the latest date they registered at the
general practitioner (GP), 1 January 1995, or their 10th
birthday, until (1) 31 December 2009, (2) their 19th
birthday, (3) the date of death or (4) the date they left
the practice.
Measurements
Outcome
We identiﬁed completed suicides using relevant Read
codes that were conﬁrmed by a date of death within
2 weeks of the suicide event date. We searched a cause
of death, if available. The list of codes was an updated
version of a published suicide code list.21 To make sure
that we did not miss any suicides, we extracted medical
records on all young people who died between the ages
of 10 and 18 and examined the free text if there was no
clear cause of death (eg, childhood cancer or a trafﬁc
accident) for possible suicides. We excluded cases where
there was doubt whether the death was due to suicide
(ie, 12 deaths which received an open verdict by the
coroner). Of these potential suicides, one patient had
records of TCA prescriptions, whereas four had records
of SSRI prescriptions in the last year. A suicide attempt,
suicidal ideation and self-harm were identiﬁed using a
Read code list that was developed in line with the pub-
lished methods and reviewed by a GP (IN).22
Exposure
We used British National Formulary (BNF) codes repre-
senting antidepressants.23 We classiﬁed antidepressants
as TCAs, SSRIs and other antidepressants according to
BNF. We excluded TCAs that were prescribed for noctur-
nal enuresis or neuropathic pain. Comparing prescrip-
tion data in THIN to dispensing data from NHS
Prescription Services showed that the mean practice
redemption rate (the percentage of recorded prescrip-
tions which were dispensed) was as high as 96.7% for
antidepressants.24
We then identiﬁed the separate episodes of anti-
depressant prescription for each individual. To
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constitute a new episode of antidepressant prescriptions,
there had to be a preceding gap of at least 3 months of
no prescriptions. We choose 3 months as a prescription
supply of antidepressants is typically 1 month or less,
and therefore a gap of at least 3 months between pre-
scriptions would quite likely represent a new episode of
antidepressant prescriptions (although not necessarily a
new episode of depression). If a person switched from
one drug to another within 3 months, this would not
constitute a new episode.
Covariates
We extracted information on gender, age and social
deprivation score (Townsend quintiles). Patients who
were prescribed TCAs for nocturnal enuresis (as con-
ﬁrmed by Read codes) were excluded. Finally, we consid-
ered consultation behaviour as a confounder. Patients
who consult infrequently with their GP, for example,
only when their prescription has run out, might not
have correctly timed records of all their events. To
correct for this, we conducted a sensitivity analysis where
we only included patients who consulted at least once a
week during the month after their ﬁrst antidepressant
prescription.
Statistical analysis
The self-controlled case series (SCCS) method
We calculated incidence rate ratios (IRRs—calculated by
dividing the incidence rate in the exposed period by the
incidence rate in the control period) for completed
suicide and suicide-related events using the self-
controlled case series (SCCS) method.25 The SCCS
method was developed to investigate associations
between acute outcomes and transient exposures, using
only data on cases. Since each case served as his/her
own control, the case–series method inherently accounts
for confounding factors that do not change over the
observation period (such as variables related to genetics,
socioeconomic status and gender). Using a Poisson
model, IRRs can be calculated for any number of prede-
ﬁned risk periods associated with the exposure, using
the time outside of these risk periods (the time when a
subject is unexposed) as a reference. A major advantage
of SCCS is that it can have high efﬁciency relative to the
retrospective cohort method from which it is derived. As
suicide-related events are rare, even in depressed
persons, the SCCS method is particularly suited for
assessing its association with antidepressants, as it
requires a much smaller number of persons to be
included. Moreover, in using a self-controlled design, we
circumvent the problem of selecting appropriate con-
trols that cohort or case-control designs encounter. In
the case of suicide-related events and antidepressants,
this has proven crucial as patients who are diagnosed as
depressed but do not receive antidepressants might
differ from patients who are receiving antidepressants in
severity of depression, a major confounder in the associ-
ation studied.
The SCCS method is limited in that it only works for
non-recurrent events when the event risk is small over the
observation period, which is the case for completed
suicide. Also, it requires variability in the age at the time of
the event: if all events were to happen at exactly the same
age (which is not the case in our study), then the method
would fail. Finally, the method only produces estimates of
relative incidence, rather than absolute incidence.
Suicide attempts, suicidal ideation and self-harm
For the analyses on suicide attempts, suicidal ideation and
self-harm, we used an adapted version of the standard
SCCS method, allowing for repeated exposures and events
and correcting by 1 year age groups.25 26 By including a
pre-exposure period, we corrected our estimates for event-
dependent exposure. If the probability of exposure to anti-
depressants is changed from baseline after an event, it
follows that the probability of the occurrence of an event is
also changed in the immediate pre-exposure period.
Including a pre-exposure period removes this time from
the baseline and corrects the estimates accordingly.
Participants who went on to commit suicide were
excluded from these analyses. Using the SCCS method,
the IRR for the three outcomes was estimated during 14
different risk periods (ﬁgure 1): baseline (or unexposed
to antidepressants); four 1-month pre-exposure periods,
the last of which is the reference; the day of prescrip-
tion; four 1-week early exposure periods; a period of
variable length to cover the remainder of the period of
exposure to the antidepressant for that episode; and
three 1-month periods of washout after the end of the
antidepressant episode. We included separate 1-week
periods at the start of the prescription as it is known that
antidepressants (especially SSRIs) take this amount of
time to have an effect.27 We also compared the effects of
individual antidepressants on the IRR of the three
suicide-related event outcomes.
Suicide
We used an adapted method (SCCS for censored
post-event exposures) to assess the effects of antidepres-
sants on childhood suicide as the original approach
cannot deal with deaths.28 This method takes account of
the early cessation of the observation period due to
deaths and accordingly corrects the IRR estimates. We
corrected for age by creating four age groups: 10–12,
13–14, 15–16 and 17–18-year-olds. We estimated IRRs for
the same risk periods as for the other outcomes, without
the four pre-exposure risk periods, and used the base-
line (time unexposed to antidepressants) as a reference.
All analyses were conducted with the use of Stata soft-
ware, V.12.1 (Stata Corp, College Station, Texas). The
scheme for THIN to obtain and provide anonymous
patient data to researchers was approved by the National
Health Service South-East Multicenter Research Ethics
Committee (MREC) in 2002 and scientiﬁc approval for
this study was obtained from CMD Medical Research’s
Scientiﬁc Review Committee in May 2011.
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RESULTS
There was a total follow-up time of 4 190 410 person-
years of 10-year-olds to 18-year-olds in THIN. In total, 81
young people were identiﬁed with a record of a com-
pleted suicide, 1496 young people with a record of
attempted suicide, 1178 young people with a record of
suicidal ideation, and 2361 with a record of intentional
self-harm. Of the young people with completed suicides,
30% were women, compared to 60%, 73% and 74% of
young people with a record of attempted suicide, sui-
cidal ideation or self-harm, respectively (table 1). There
was no signiﬁcant difference in age of ﬁrst event
between the different outcomes. The data were com-
plete for all variables except Townsend scores, which
were missing for 92 (2%) persons. Owing to the small
numbers, we were not able to analyse antidepressants
other than SSRIs or TCAs.
Attempted suicide, suicidal ideation and self-harm
For attempted suicide, suicidal ideation and self-harm,
there were similar patterns between young people who were
prescribed SSRIs and TCAs (table 2 and ﬁgure 2A–C):
there was an upward trend in IRR during pre-exposure; a
peak on the day of prescription; a stable or slightly
increased rate ratio during the ﬁrst weeks of prescription;
and during the washout period, the levels decreased
again. The increase on prescription day was highest for
young people with a record of suicidal ideation (SSRIs:
IRR=33.4, 95% CI 23.6 to 47.4; TCAs: IRR=14.0, 95% CI
6.8 to 28.8). There were no signiﬁcant differences
between IRRs for any of the event types for any risk
periods. Patterns were similar between individual SSRIs
(ﬂuoxetine, citalopram, sertraline and paroxetine,
results in the appendix).
The IRR for each type of event has a strong relation
with age. When compared to 15-year-olds to 16-year-olds,
17-year-olds to 18-year-olds are twice as likely to
attempt suicide (IRR=1.90, 95% CI 1.6 to 2.3
and IRR=2.1, 95% CI 1.7 to 2.5 for SSRIs and TCAs,
respectively), but those between 10 and 12 years old are
less likely to attempt suicide (IRR=0.3, 95% CI 0.2 to 0.4
and IRR=0.2, 95% CI 0.1 to 0.2 for SSRIs and TCAs,
respectively). Patterns were similar for the other
outcomes.
Figure 1 Risk periods included in self-controlled case series analysis for attempted suicide, suicidal ideation and self-harm and
suicide. 1=baseline; 2–5=1 month pre-exposure periods; 6=prescription day; 7–10=four 1 week exposure periods; 11=remainder
of antidepressant exposure; 12–14=three 1-month washout periods.
Table 1 Demographics by category of suicidal or self-harming behaviour
Completed
suicide 81
Attempted
suicide 1496
Suicidal
ideation 1178 Self-harm 2361
General population
952 892
Girls (%) 24 (29.6) 1089 (72.8) 708 (60.1) 1752 (74.2) 461 610 (48.4)
Number of taking ADs (%) 19 (23.1) 527 (36.6) 578 (52.8) 128 (5.7) 27 632 (2.9)
Number of depressed (%) 21 (25.9) 728 (48.7) 819 (69.5) 173 (7.3) 41 101 (4.3)
Number of Townsend
score (%)
1 (most affluent) 20 (24.7) 266 (17.8) 193 (16.4) 442 (18.7) 227 178 (23.8)
2 5 (6.2) 240 (16.0) 202 (17.2) 405 (17.2) 198 686 (20.9)
3 13 (16.1) 286 (19.1) 236 (20.0) 452 (19.1) 184 934 (19.4)
4 25 (30.9) 364 (24.3) 283 (24.0) 571 (24.2) 169 792 (17.8)
5 (most deprived) 16 (19.8) 316 (21.1) 241 (20.5) 446 (18.9) 120 116 (12.6)
Median age in years at
(first) event (5–95%)
16.8 (12.0–18.8) 16.5 (12.9–18.7) 16.7 (12.0–18.7) 15.9 (12.6–18.7) –
Median time in study in
years (5–95%)
3.5 (0.2–8.4) 5.5 (1.4–9.0) 5.9 (1.5–9.0) 5.9 (1.5–9.0) –
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There were no statistically-signiﬁcant differences
between boys and girls for either SSRIs or TCAs (results
not shown). A small group of 25 patients had a prescrip-
tion for an antidepressant and a primary diagnosis other
than depression (obsessive compulsive disorder (OCD)
or anxiety). Owing to the small size of this group, we did
not perform a subgroup analysis. Finally, restricting the
analyses to regular consulters (those who consulted at
least ﬁve times during the ﬁrst 4 weeks of prescription)
did not alter the effect estimates. Of the young people
with a record of attempted suicide or intentional self-
harm, 33% were regular consulters, compared to 49% of
young people with a record of suicidal ideation.
Suicide
Using an expected suicide rate of 3.28 (95% CI 3.12 to
3.43) per 100 000 person-years in the UK population of
10-year-olds to 18-year-olds,29 we would expect 137 (95%
CI 131 to 144) completed suicides in our study popula-
tion. However, 41% of suicides registered by the Ofﬁce
of National Statistics were of undetermined intent,
leaving 59% or 81 (95% CI 77 to 85) expected suicides
that received a verdict by a coroner. This estimate corre-
sponds to the number of 81 completed suicides we iden-
tiﬁed between 1995 and 2009 within the THIN database.
Of the 81 young people with a completed suicide, 21
(26%) had a prior record of a depression diagnosis or
depression symptoms. Nineteen young people (23%)
were taking antidepressants in the year before their
suicide, and 11 (14%) were still taking them at the time
of or shortly before their suicide. There was also a high
proportion of young people with (a history of) behav-
iour disorders 16 (20%), a history of self-harm 8 (10%),
a psychiatric referral 19 (23%), a hyperkinetic disorder
5 (6%) or an eating disorder 3 (4%).
There were no completed suicides within the risk
periods for antidepressants other than SSRIs (table 3).
Eleven (14%) completed suicides were within the risk
periods. Similar to the results from the data on
suicide-related events, IRR was highest on the day of pre-
scription (IRR=42.5, 95% CI 4.5 to 403.4). There were
no events in the ﬁrst 2 weeks of the SSRI episode, but
there was an increased rate ratio in week 3 (IRR=8.0,
95% CI 0.8 to 76.7, based on a single case) and a statis-
tically signiﬁcant increase in week 4 (IRR=11.3, 95% CI
1.1 to 115.6, though based on two cases). After the
fourth week of the SSRI episode, IRR decreased and
returned to baseline levels during washout. There were
no signiﬁcant differences between age groups.
DISCUSSION
Overall, there are no systematic differences between
TCAs and SSRIs in IRRs for attempted suicide, suicidal
ideation or intentional self-harm, and apart from an
increase common to both TCAs and SSRIs on the day of
prescription, rates were not statistically signiﬁcantly dif-
ferent from pre-exposure levels. The pattern of IRRs for
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completed suicides for the 11 people prescribed SSRIs
was similar to that found in attempted suicide, suicidal
ideation and self-harm. However, concerns regarding
antidepressants need to be weighed against the risk of
untreated depression.
Pre-exposure IRRs for attempted suicide, suicidal idea-
tion and self-harm appeared to be marginally higher,
though not statistically signiﬁcant, for SSRIs compared
to TCAs. This could be because young people who are
deemed to be more at risk of suicide-related events
could preferentially be prescribed SSRIs over TCAs,
given TCAs’ toxicity in overdose.17
The high IRRs on the day of antidepressant prescrip-
tion for all three non-fatal outcomes could be an artefact
of GP-recording behaviour. Rather than the antidepres-
sant causing the suicide-related events, the event is an
indication for the GP to prescribe the drug and to
record depression in the electronic records on the same
day. As antidepressants should only be prescribed by
child and adolescent psychiatrics (2005 NICE guide-
lines6), this artefact could also arise when GPs continue
a prescription started in secondary care and record the
initial indication when ﬁrst prescribing this drug.
Up to the fourth week of prescription, the IRRs for
attempted suicide, suicidal ideation and self-harm
remained around the levels experienced during the pre-
exposure period. Considering that suicide-related events
are common in young depressed people, some suicidal
and self-harm events would be expected irrespective of
whether SSRIs are prescribed or not.30 The rate of
Figure 2 Incidence rate ratios for (A) attempted suicide, (B) suicidal ideation and (C) self-harm for tricyclic antidepressants and
selective serotonin inhibitors. The month before a prescription was issued (pre-exposure 4) was used as the reference.
Table 3 Incidence rate ratios (IRRs) for completed
suicide by risk period and age
Risk period
Censoring model
IRR (95% CI)
Number of
deaths*
Prescription day 42.52 (4.48 to 403.43) 5
Week 1 No events 0
Week 2
Week 3 8.00 (0.84 to 76.71) 1
Week 4 11.25 (1.09 to 115.58) 2
Rest of AD
episode
5.42 (0.57 to 51.94) 1
Washout 1 2.27 (0.24 to 21.76) 1
Washout2 2.08 (0.22 to 19.69) 1
Age groups Number of total
deaths†
10 to 12 0.61 (0.21 to 1.77) 8
13 to 14 1.14 (0.45 to 2.90) 15
15 to 16 Reference 21
17 to 18 0.41 (0.12 to 1.39) 37
*Number of suicides during risk periods (only includes youths who
were taking antidepressants at the time of suicide, or those who
had recently stopped).
†Number of suicides by age category.
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suicide-related events decreased when the prescriptions
were stopped. Given the nature of the data, it is difﬁcult
to know whether the SSRIs were causing suicide-related
events and these events improved when the SSRIs were
discontinued, or if the SSRIs were discontinued when
the young person’s depression (and as a consequence
the risk of suicide-related events) improved.
There are three possible explanations for the slightly
increased IRRs during the ﬁrst month of prescription.
One is that the SSRIs fail to relieve the risk of
suicide-related events associated with depression because
of a lag in the antidepressant effect, an incomplete
response, or a treatment-resistant depression. It is known
that SSRIs take a couple of weeks to reach their full anti-
depressant effects and hence reduce the risk of
suicide-related events.27
A second possibility is that the SSRIs generate a novel
set of suicidal emotions or behaviours. Early improve-
ments in clinical depression can lead to a person acting
on existing suicidal feelings. This activation syndrome
has been described for TCAs and SSRIs, and is widely
recognised by psychiatrists as well as the FDA.31 32 While
patients might be demotivated and demoralised at the
height of their depression, when they start treatment
they become more active during the ﬁrst weeks of taking
the drug. During this time, the antidepressant effect of
the medication will not have reached its full effect,
resulting in persistent depression but simultaneous
increased activity. This could lead to a greater risk of
suicide-related events until the full effects of antidepres-
sants are realised a few weeks later.31
Several studies and systematic reviews have shown an
age effect in the risk of suicide-related events with the
use of SSRIs. In adults and the elderly, the risk is neutral
or SSRIs show a protective effect, while in adolescents
and young adults there appears to be an increased risk
of suicide-related events.9 15 33
Although we did not ﬁnd a statistically signiﬁcantly sus-
tained increase in suicide-related events with either
SSRIs or TCAs, negative outcomes did not appear to be
decreased either—although our study was not designed
to assess this. This is in line with the Cochrane reviews
on both drug groups: the review on TCAs concludes that
these drugs are not useful in treating depression in pre-
pubertal children, and that there is only marginal evi-
dence to support the use of TCAs in adolescents,
although the magnitude of the effect is likely to be mod-
erate at best.3 Similarly, it is unclear what the effect is of
SSRIs on suicide completion. Although evidence from
clinical trials implies an increased risk of suicide-related
outcomes (but not completed suicide), the evidence for
this association is of low quality.34
Comparison to other studies
Our results build on the ﬁndings of Schneeweis et al13
They found no statistically signiﬁcant differences in the
relative risk of attempted and completed suicide
between different types of antidepressants (ﬂuoxetine,
citalopram, ﬂuvoxamine, paroxetine, sertraline and
TCAs) when examining 266 attempted and three com-
pleted suicides. Moreover, an ecological study found no
change in rates of completed suicides or hospital admis-
sions for self-harm following the CSM advice,35 suggest-
ing that there is no, or only a weak, relationship with
antidepressant prescriptions. Our ﬁndings are also
similar to those of Simon et al36 who used computerised
health plan records and reported the highest rates for
attempted suicide in the month before prescription,
rather than after start of the prescription. Finally, a
meta-analysis37 found that, of 27 paediatric randomised
controlled trials on antidepressants prescribed for MDD,
OCD and non-OCD anxiety disorders, the risk of sui-
cidal ideation or attempt among patients on placebo was
greater in trials assessing MDD. Although this difference
in baseline risk for suicide-related events was not
statistically-signiﬁcant, it could indicate that a part of the
association between antidepressants and suicide-related
events can be explained by the underlying disease,
rather than the drug. Importantly, the authors con-
cluded that relative to placebo, the beneﬁts (though
only modest in MDD) outweigh the risks from suicidal
ideation/suicide attempts. Owing to the small numbers
of patients with primary diagnoses of OCD and anxiety
disorders, we could not repeat the meta-analysis’s sub-
group comparison.
Main strength and limitations
The main strength of this study is its sample size that
enables the examination of outcomes separately by com-
pleted and attempted suicide, suicidal ideation and self-
harm, as well as by individual antidepressants. However,
even in using a database as large as THIN, we could
identify only a small number of completed suicides,
leading to limited power in that analysis. Similarly, power
was limited for analysing individual antidepressants,
which are presented in the appendix. Nevertheless, the
use of the SCCS method allows us to control for time-
independent confounders, making our estimations more
robust.
A limitation to our study is that the THIN database
only provides data on antidepressant prescriptions. We
do not know whether the prescriptions were dispensed,
or whether the patients adhered to the prescription.
However, though it is known that adherence levels are
around 50% for young people taking SSRIs, and even
lower for TCAs,38 our data do represent a real-life situ-
ation. Moreover, by assessing episodes of antidepressant
prescription, we take account of multiple prescriptions
per patient, which increases the likelihood of adherence,
as we expect patients who are not taking their medica-
tion will not return for a new prescription.
Moreover, it is known that suicide-related events are
often missed in clinical assessment.39 However, it is quite
likely that the most severe forms (attempted suicides
and severe suicidal ideation) are most likely to be
recorded by clinicians. Also, in using a self-controlled
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design, we decrease the chance of misclassifying con-
trols. There is some suggestion that antidepressants
might speciﬁcally increase suicide-related events in
patients who did not experience these events prior to
starting antidepressant treatment. Owing to the variation
in the clinicians’ assessment and recording of (the
absence of) suicide-related events, we could not
examine this hypothesis using this database.
Furthermore, the relatively low number of young people
who had a prescription for an antidepressant at the time
of their suicide-related event limits the interpretation of
our results. However, Windfuhr et al29 also found that
mental health service contact was low in juveniles who
committed suicide: only 14% contacted services in the
year before they died. Finally, we were not able to
account for changes in depression severity over time as
this is poorly recorded.
CONCLUSION
Our study shows that there are similar IRR patterns for
attempted suicide, suicidal ideation and self-harm for
SSRIs and TCAs. Also, the pattern for completed suicides
associated with SSRI prescriptions is similar, though there
are no records of completed suicides within our prede-
ﬁned risk periods for TCAs. Although the CSM’s warning
was a sensible cautionary recommendation at the time, it
appears that the current line of evidence suggests a
reverse causality: it is the underlying depression that
leads to suicide-related events and the prescription of
antidepressants, although a causal effect of SSRIs or no
effect at all cannot be ruled out. Moreover, even if anti-
depressant drugs would temporarily increase the risk of
suicide-related events in young persons, the risk posed by
untreated depression is far greater. In conclusion, our
results indicate that the association of suicide-related
events associated with antidepressants occurs primarily
around the day of prescription, suggesting depression
severity and GP-recording behaviour as the culprit rather
than antidepressants, and thus warrants a re-evaluation of
the current guidelines regarding the prescription of
SSRIs in primary care.
RECOMMENDATION
Our results are not deﬁnitive, and due to the rare nature
of the outcome and the intricacies of the problem
studied, it is difﬁcult to think of a single study or study
design that will be able to provide a satisfying answer to
the problem at hand. It is possible that the creation of a
pragmatic registry, similar to that proposed by van Staa
et al40 in their pragmatic randomised trial, will allow for
active pharmacovigilance. Such a system would, at low
cost and with no additional burden on clinician, health
service or patient time, facilitate long-term, anonymous,
unobtrusive follow-up for major clinical outcomes. As
such, clinicians would be prompted to monitor and
record (the absence of) suicide-related events and idea-
tion more regularly and closely, using similar outcome
measurements as those used in clinical trials, as well as
(changes in) depression severity.
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